The abbott test is NOT an in home test, it must be
Post# of 9123
(Total Views: 592)
Posted On: 08/27/2020 4:47:33 PM
The abbott test is NOT an in home test, it must be administered by trained personnel
whereas NNLX test is expected to be configured to allow it to be used in home w nasal swab
re abbots claims of 97-98% accuracy, we dont know what parameters they used to make those claims - and i will have to look at that again when i have time
other companies have PR'd initial claims only to have those claims fail later-read recently about problems w remsdevir (sp?)
both of the other company tests posted today are antigen tests .
dd re the limitations of antigen tests has been posted by our medical experts mits and mach both from their own knowledge and from articles
-such dd and articles have stated that antigens likely means a person has been exposed to the virus BUT CANNOT DEFINITIVELY SAY WHETHER THAT EXPOSURE IS PAST OR CURRENT-and recently I read about the first confirmed case of reinfection by covid 19
so presence of antigens supposedly means was exposed but cannot say whether there is a current infection large enough to be symptomatic and antigen tests have missed those who are asymptomatic
The following article again mentions some of the limitations of antigen tests .
presence of antigens means a person has been exposed to the virus
the article itself mentions that PCR is the gold standard and is superior to antigen tests- well, NNLX test is superior to PCR as articles and commentary by our medical experts mits (who has publicly revealed himself on this board to be an M.D. on the front lines-he did so reluctantly in response to a question by a basher) and mach have abundantly noted
so using a little logic called a syllogism:
antigen is inferior to PCR
PCR is inferior to NNLX's covid test
therefore NNLX's test is superior to an antigen test
so as i have said many times -the immensity of this unique covid situation opens the door for many tests by many co's
https://www.wcvb.com/article/5-investigates-c...9/33538332
I have never understood the knee jerk fear and run reaction of humans especially those based on false or incomplete information- not a good place for those in the market to be
yes NNLX does not have the money to bring its test to market -thats why NNLX has partnered with 2 other organizations- as Sierra has previously pointed out it we may know who is the Houston lab -we dont know who the california diagnostic company is
and NNLX recent update explains some of the purposes for the NDA's- its quite common in penny land for those who have ill will towards a co or for bashers shorters etc to interfere in and destroy company relationships once they know who those relationships are
Small co's like NNLX are limited by finances in ways investors -from reading tens of thousands of posts over 11 years- dont understand.
Without an understanding of those limitations investors almost always find an easy target for their frustrations-and bashers dont need frustrations to target a co
I'm a dd type of person w a very long attention span.. I had no interest in stocks whatsoever-can you say, 'less than zero"- when my best friend dragged me into pennies to help him avoid foreclosure once the great recession destroyed his otherwise successful business- he was intelligent but like many penny traders he did no dd-so in looking at the co's he was trading (and very successfully while the market was rising form its nadir) I was shocked by their poor financial stats and read tens of thousands of filings by thousands of companies - and learned how the market -especially the penny market works- to help him.
penny investors have no concept -cannot imagine- the length and breadth of dd done by big co's before they even decide to enter into discussions w another company
many investors here dont understand this paradigm and thus they blame the usual target- the ceo
so to take the blame off the ceo i have to bring up a subject for which i have been excoriated by longs before-(and I've been long NNLX ca 10 years) NNLX no info classification
so when Bret issued the ca 6-3-20 PR to stir up additional interest w other companies- what's the first thing other potentially interested co's are going to do- its called dd!! you may have heard of it-its not something to be afraid of
But those companies-other than the website NNLX purposefully updated so it would be the key part of the PR- immediately run into a brick wall they do not understand!!!!!- the otc no info classification . Most big co's will immediately discount -reject any kind of relationship w an otc co-let alone a no info class!!!
big co's go to any meeting w another co w exhaustive dd so they can do what humans do best -selfishly manipulate push pressure influence blackmail etc the opposing party
those co's can find no info on NNLX beyond NNLX's website - so their paradigm for operating does not exist re NNLX- so they immediately back off - do I have to laboriously explain the internal big co conversations for you??
I understand NNLX's paradigm also-NNLX -unlike thousands of other pennies which have capitulated due to excessive costs-NNLX has avoided those pitfalls-but everything comes at a price- the cost savings NNLX has instituted to survive also creates problems in dealing w larger co's -including the contempt of larger co's for otc co's -esp no info classification
its a chicken and the egg problem- NNLX reduces costs to survive -thats what they have to do
obviously big co's -w their armies of PI's and lawyers- cant find enough on NNLX or Bret etc to blackmail NNLX- so those co's have no place to go in dealing w NNLX!!!- they are in totally unfamiliar territory!!!
-they are not visionaries like NNLX-they are businessmen and lawyers-both such groups adamantly oppose those who can think (those w vision who can think outside the tiny one dimensional box such groups by pre inclination and training have placed themselves)
Friday, August 7, 2020 10:29:11 AM
Post#
6969
of 6989
(Total Views: 134)
Posted On: 08/07/2020 8:22:19 AM
Posted By: Eudius
Update
NanoLogix Sub 1-Hour Covid-19 Detection Test Further Developments
NanoLogix Begins Collaborative Efforts With Diagnostic Company and an Independent Laboratory
NanoLogix announces it has begun working with two entities to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses. One is a West Coast diagnostic company and the other a long-established independent Houston laboratory.
The overall intent of this work is to obtain results to enable a detailed submission of those results to the US FDA for the purpose of receiving an Emergency Use Authorization, enabling use of the technology as a Point of Care (POC) rapid test. Secondary benefits should be publication of the resulting data in the form of at least two peer-reviewed science/medical journal papers. Grant applications are anticipated by at least one of the partners to the work. The projections for the timeline for the work range from one+ month for the independent laboratory to more than three months for the diagnostic company.
While we have achieved results in less than one hour with our own laboratory work, indications from one of the entities are that the test can potentially be streamlined to the point where results may be obtained in as little as twenty minutes in a form that makes the test more user and consumer friendly. This projected ease of use positions the assay for potential home use if and when it is approved by the FDA.
NanoLogix has entered into mutual confidentiality agreements with both involved groups. We faithfully respect those agreements as essential to the success of business and technology development. In the past, when we have released information mentioning arrangements with others, such as the US EPA, the University of Texas Health Science Center in Houston, Battelle Biomedical research Center, and individuals recently employed or otherwise associated with NanoLogix, those groups began receiving calls and contacts from persons identifying themselves as shareholders of NanoLogix. The calls ranged from in subject from simple curiousity to demands to reveal the nature of the technology development and business relationship with NanoLogix. The effects were potentially damaging to NanoLogix and its interests, to include investors. We will not release further information regarding the recent associations until all parties are prepared to do so.
This press release or update contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Read More: https://investorshangout.com/post/view?id=585...z6URlniueu
Posted On: 07/09/2020 12:59:26 PM
Posted By: Fibonacci233
NanoLogix Welcomes Dr. Sebastian Faro to its Board of Directors
Sebastian Faro, MD joins as Director to Assist with Development Efforts
NanoLogix is very pleased to announce that Sebastian Faro, M.D, Ph.D. has joined our Board of Directors. Dr. Faro brings over forty-five years of medical experience and an extensive body of knowledge concerning infectious diseases to the NanoLogix Science Advisory Board. Dr. Faro previously served as Chief of Obstetrics and Gynecology at LBJ Hospital in Houston, Texas and was Vice-Chair of the Obstetrics, Gynecology, and Reproductive Sciences Department at the University of Texas Health Science Center at Houston. Dr. Faro received his PhD in botany at the University of Iowa and completed his postdoctoral fellowship training at the New York Botanical Garden. He then completed medical school and residency training at Creighton University. He served as director of infectious disease at both Louisiana State University and the Baylor College of Medicine, and as Department Chair for the University of Kansas and Rush-Presbyterian-St. Luke's Medical Center.
Dr. Faro is not only a member of a number of professional societies, but also served as President of the Infectious Disease Society for Obstetrics and Gynecology. He has published at least 149 articles in peer-reviewed medical publications and served as Editor-in-Chief of Infectious Diseases in Obstetrics and Gynecology for 13 years. He is also an Editor of the current editions of the following textbooks: Infectious Diseases in Women; Benign Diseases of the Vulva and Vagina; and Infections in Pregnancy.
Dr. Faro stated " I am looking forward to working with NanoLogix as it puts its efforts into providing solutions to the testing problems existing with the Coronavirus Pandemic."
Read More: https://investorshangout.com/post/view?id=582...z6RlLBP54N
Posted On: 06/03/2020 5:00:23 PM
Posted By: Machiavelli20
Re: rayludwiczak #6382
The key is that the prior technologies were either ones that had a reasonably narrow competitive edge over ones that major companies and suppliers had already locked in and were receiving remittances of some sort (kickbacks) or was in a niche that those committed to PCR and other type technologies had a close enough edge that they could ignore the development.
This diagnostic technology is so accurate and comprehensive across a number of critical categories that there is nothing competitive --except when the others cheat and have to be sued for patent infringement. My mantra is that I trust no one. Virtually everyone can be bought when the $$ are enough. So, given the technology as Faro and James Rogers (long term Battelle) describes, there is no equivalent in a critical global emergency. NNLX possesses the tech and has filed for the provisional patent and EUA for it to gain legal protection, there is an incredible need for this specific patented technology in the US, Europe, China (steals), etc. so the reality is that one way or another through a large scale marketing partner or a longer term law suit NNLX "wins". Although experience keeps us from being insane, $.08 or .15, or .50 simply does not make sense. Although we live in an insane nonsensical world. So unless you have a need for $500-$1500 gain you would be nuts to bail. But go ahead.
Posted On: 06/03/2020 1:07:25 PM
Posted By: Eudius
https://www.prnewswire.com/news-releases/nano..._cleartime
Posted On: 05/31/2020 10:12:21 AM
Posted By: Sierra
Another email update. I'm sure everyone has seen the summary. Nice info but it won't move the SP up.
NanoLogix and COVID-19 Testing News
Realizing that many of our shareholders are from areas where they may not be aware of news coverage of NanoLogix developments, the Company is pleased to present the following links to articles written and interviews done during the month of May.
Warren Tribune:
https://www.tribtoday.com/news/local-news/202...d-19-test/
Youngstown Vindicator:
https://www.vindy.com/opinion/brenda-j-linert...ng-valley/
Youngstown Vindicator:
https://www.vindy.com/news/local-news/2020/05...f-viruses/
Channel 27 (CBS) Youngstown:
https://www.youtube.com/watch?v=LrPoqVAH1No
Fox News 13 Tampa:
https://www.youtube.com/watch?v=HVcSchmwXgc
The Youngstown Vindicator is now published by the Warren Tribune, so while we link to one example, duplicate articles can be found for the same dates for both newspapers.
Read More: https://investorshangout.com/post/view?id=578...z6OATHH9e9
new website: https://nanologix.com/
https://www.vindy.com/news/local-news/2020/05...f-viruses/
Posted On: 05/18/2020 12:35:54 PM
Posted By: Sierra
Re: ronclaw47 #6162
NanoLogix Sub 1-Hour Covid-19 Detection Test Now
Patent-Pending
Patent Application Filed Under New COVID-19 Prioritized Examination Pilot Program
NanoLogix is pleased to announce the filing of a patent application for use in the rapid testing for the Covid-19 virus. The application was filed under a new program instituted May 14th by the US Patent and Trademark Office. Now that Patent-Pending status has been obtained, we can reveal aspects of the technology that we were unable to mention in a prior update.
This Rapid Viral Assay is a modified ELISA technology that is not the same as our N-Assay modified ELISA.
While the initial focus for development was for the COVID-19 virus, it became obvious that the technology is not limited to one virus, but can be configured for many different viruses, such as HIV, HPV, Hepatitis, MERS, SARS-1 and others. As per the patent filing, the description is "Without Limitation".
An additional aspect of the test is that for the Home-Test configuration, we anticipate the potential of 30-minute results using a nasopharyngeal swab sample or saliva.
Jonathan Faro, MD, PhD., our Chief Medical Officer stated "We are extremely excited over this technology development, as it is a novel approach in diagnostics that provides a solution to the inherent problems with false positives and false negatives present in those tests currently being used in the war against COVID-19."
The US Patent Office program under which the filing was done can be accessed through the following link:
https://www.federalregister.gov/documents/202...program?
Read More: https://investorshangout.com/post/view?id=577...z6N0UZkNXc
Read More: https://investorshangout.com/Nanologix-Inc-NN...z6WLcA5KqR
whereas NNLX test is expected to be configured to allow it to be used in home w nasal swab
re abbots claims of 97-98% accuracy, we dont know what parameters they used to make those claims - and i will have to look at that again when i have time
other companies have PR'd initial claims only to have those claims fail later-read recently about problems w remsdevir (sp?)
both of the other company tests posted today are antigen tests .
dd re the limitations of antigen tests has been posted by our medical experts mits and mach both from their own knowledge and from articles
-such dd and articles have stated that antigens likely means a person has been exposed to the virus BUT CANNOT DEFINITIVELY SAY WHETHER THAT EXPOSURE IS PAST OR CURRENT-and recently I read about the first confirmed case of reinfection by covid 19
so presence of antigens supposedly means was exposed but cannot say whether there is a current infection large enough to be symptomatic and antigen tests have missed those who are asymptomatic
The following article again mentions some of the limitations of antigen tests .
presence of antigens means a person has been exposed to the virus
the article itself mentions that PCR is the gold standard and is superior to antigen tests- well, NNLX test is superior to PCR as articles and commentary by our medical experts mits (who has publicly revealed himself on this board to be an M.D. on the front lines-he did so reluctantly in response to a question by a basher) and mach have abundantly noted
so using a little logic called a syllogism:
antigen is inferior to PCR
PCR is inferior to NNLX's covid test
therefore NNLX's test is superior to an antigen test
so as i have said many times -the immensity of this unique covid situation opens the door for many tests by many co's
https://www.wcvb.com/article/5-investigates-c...9/33538332
I have never understood the knee jerk fear and run reaction of humans especially those based on false or incomplete information- not a good place for those in the market to be
yes NNLX does not have the money to bring its test to market -thats why NNLX has partnered with 2 other organizations- as Sierra has previously pointed out it we may know who is the Houston lab -we dont know who the california diagnostic company is
and NNLX recent update explains some of the purposes for the NDA's- its quite common in penny land for those who have ill will towards a co or for bashers shorters etc to interfere in and destroy company relationships once they know who those relationships are
Small co's like NNLX are limited by finances in ways investors -from reading tens of thousands of posts over 11 years- dont understand.
Without an understanding of those limitations investors almost always find an easy target for their frustrations-and bashers dont need frustrations to target a co
I'm a dd type of person w a very long attention span.. I had no interest in stocks whatsoever-can you say, 'less than zero"- when my best friend dragged me into pennies to help him avoid foreclosure once the great recession destroyed his otherwise successful business- he was intelligent but like many penny traders he did no dd-so in looking at the co's he was trading (and very successfully while the market was rising form its nadir) I was shocked by their poor financial stats and read tens of thousands of filings by thousands of companies - and learned how the market -especially the penny market works- to help him.
penny investors have no concept -cannot imagine- the length and breadth of dd done by big co's before they even decide to enter into discussions w another company
many investors here dont understand this paradigm and thus they blame the usual target- the ceo
so to take the blame off the ceo i have to bring up a subject for which i have been excoriated by longs before-(and I've been long NNLX ca 10 years) NNLX no info classification
so when Bret issued the ca 6-3-20 PR to stir up additional interest w other companies- what's the first thing other potentially interested co's are going to do- its called dd!! you may have heard of it-its not something to be afraid of
But those companies-other than the website NNLX purposefully updated so it would be the key part of the PR- immediately run into a brick wall they do not understand!!!!!- the otc no info classification . Most big co's will immediately discount -reject any kind of relationship w an otc co-let alone a no info class!!!
big co's go to any meeting w another co w exhaustive dd so they can do what humans do best -selfishly manipulate push pressure influence blackmail etc the opposing party
those co's can find no info on NNLX beyond NNLX's website - so their paradigm for operating does not exist re NNLX- so they immediately back off - do I have to laboriously explain the internal big co conversations for you??
I understand NNLX's paradigm also-NNLX -unlike thousands of other pennies which have capitulated due to excessive costs-NNLX has avoided those pitfalls-but everything comes at a price- the cost savings NNLX has instituted to survive also creates problems in dealing w larger co's -including the contempt of larger co's for otc co's -esp no info classification
its a chicken and the egg problem- NNLX reduces costs to survive -thats what they have to do
obviously big co's -w their armies of PI's and lawyers- cant find enough on NNLX or Bret etc to blackmail NNLX- so those co's have no place to go in dealing w NNLX!!!- they are in totally unfamiliar territory!!!
-they are not visionaries like NNLX-they are businessmen and lawyers-both such groups adamantly oppose those who can think (those w vision who can think outside the tiny one dimensional box such groups by pre inclination and training have placed themselves)
Friday, August 7, 2020 10:29:11 AM
Post#
6969
of 6989
(Total Views: 134)
Posted On: 08/07/2020 8:22:19 AM
Posted By: Eudius
Update
NanoLogix Sub 1-Hour Covid-19 Detection Test Further Developments
NanoLogix Begins Collaborative Efforts With Diagnostic Company and an Independent Laboratory
NanoLogix announces it has begun working with two entities to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses. One is a West Coast diagnostic company and the other a long-established independent Houston laboratory.
The overall intent of this work is to obtain results to enable a detailed submission of those results to the US FDA for the purpose of receiving an Emergency Use Authorization, enabling use of the technology as a Point of Care (POC) rapid test. Secondary benefits should be publication of the resulting data in the form of at least two peer-reviewed science/medical journal papers. Grant applications are anticipated by at least one of the partners to the work. The projections for the timeline for the work range from one+ month for the independent laboratory to more than three months for the diagnostic company.
While we have achieved results in less than one hour with our own laboratory work, indications from one of the entities are that the test can potentially be streamlined to the point where results may be obtained in as little as twenty minutes in a form that makes the test more user and consumer friendly. This projected ease of use positions the assay for potential home use if and when it is approved by the FDA.
NanoLogix has entered into mutual confidentiality agreements with both involved groups. We faithfully respect those agreements as essential to the success of business and technology development. In the past, when we have released information mentioning arrangements with others, such as the US EPA, the University of Texas Health Science Center in Houston, Battelle Biomedical research Center, and individuals recently employed or otherwise associated with NanoLogix, those groups began receiving calls and contacts from persons identifying themselves as shareholders of NanoLogix. The calls ranged from in subject from simple curiousity to demands to reveal the nature of the technology development and business relationship with NanoLogix. The effects were potentially damaging to NanoLogix and its interests, to include investors. We will not release further information regarding the recent associations until all parties are prepared to do so.
This press release or update contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Read More: https://investorshangout.com/post/view?id=585...z6URlniueu
Posted On: 07/09/2020 12:59:26 PM
Posted By: Fibonacci233
NanoLogix Welcomes Dr. Sebastian Faro to its Board of Directors
Sebastian Faro, MD joins as Director to Assist with Development Efforts
NanoLogix is very pleased to announce that Sebastian Faro, M.D, Ph.D. has joined our Board of Directors. Dr. Faro brings over forty-five years of medical experience and an extensive body of knowledge concerning infectious diseases to the NanoLogix Science Advisory Board. Dr. Faro previously served as Chief of Obstetrics and Gynecology at LBJ Hospital in Houston, Texas and was Vice-Chair of the Obstetrics, Gynecology, and Reproductive Sciences Department at the University of Texas Health Science Center at Houston. Dr. Faro received his PhD in botany at the University of Iowa and completed his postdoctoral fellowship training at the New York Botanical Garden. He then completed medical school and residency training at Creighton University. He served as director of infectious disease at both Louisiana State University and the Baylor College of Medicine, and as Department Chair for the University of Kansas and Rush-Presbyterian-St. Luke's Medical Center.
Dr. Faro is not only a member of a number of professional societies, but also served as President of the Infectious Disease Society for Obstetrics and Gynecology. He has published at least 149 articles in peer-reviewed medical publications and served as Editor-in-Chief of Infectious Diseases in Obstetrics and Gynecology for 13 years. He is also an Editor of the current editions of the following textbooks: Infectious Diseases in Women; Benign Diseases of the Vulva and Vagina; and Infections in Pregnancy.
Dr. Faro stated " I am looking forward to working with NanoLogix as it puts its efforts into providing solutions to the testing problems existing with the Coronavirus Pandemic."
Read More: https://investorshangout.com/post/view?id=582...z6RlLBP54N
Posted On: 06/03/2020 5:00:23 PM
Posted By: Machiavelli20
Re: rayludwiczak #6382
The key is that the prior technologies were either ones that had a reasonably narrow competitive edge over ones that major companies and suppliers had already locked in and were receiving remittances of some sort (kickbacks) or was in a niche that those committed to PCR and other type technologies had a close enough edge that they could ignore the development.
This diagnostic technology is so accurate and comprehensive across a number of critical categories that there is nothing competitive --except when the others cheat and have to be sued for patent infringement. My mantra is that I trust no one. Virtually everyone can be bought when the $$ are enough. So, given the technology as Faro and James Rogers (long term Battelle) describes, there is no equivalent in a critical global emergency. NNLX possesses the tech and has filed for the provisional patent and EUA for it to gain legal protection, there is an incredible need for this specific patented technology in the US, Europe, China (steals), etc. so the reality is that one way or another through a large scale marketing partner or a longer term law suit NNLX "wins". Although experience keeps us from being insane, $.08 or .15, or .50 simply does not make sense. Although we live in an insane nonsensical world. So unless you have a need for $500-$1500 gain you would be nuts to bail. But go ahead.
Posted On: 06/03/2020 1:07:25 PM
Posted By: Eudius
https://www.prnewswire.com/news-releases/nano..._cleartime
Posted On: 05/31/2020 10:12:21 AM
Posted By: Sierra
Another email update. I'm sure everyone has seen the summary. Nice info but it won't move the SP up.
NanoLogix and COVID-19 Testing News
Realizing that many of our shareholders are from areas where they may not be aware of news coverage of NanoLogix developments, the Company is pleased to present the following links to articles written and interviews done during the month of May.
Warren Tribune:
https://www.tribtoday.com/news/local-news/202...d-19-test/
Youngstown Vindicator:
https://www.vindy.com/opinion/brenda-j-linert...ng-valley/
Youngstown Vindicator:
https://www.vindy.com/news/local-news/2020/05...f-viruses/
Channel 27 (CBS) Youngstown:
https://www.youtube.com/watch?v=LrPoqVAH1No
Fox News 13 Tampa:
https://www.youtube.com/watch?v=HVcSchmwXgc
The Youngstown Vindicator is now published by the Warren Tribune, so while we link to one example, duplicate articles can be found for the same dates for both newspapers.
Read More: https://investorshangout.com/post/view?id=578...z6OATHH9e9
new website: https://nanologix.com/
https://www.vindy.com/news/local-news/2020/05...f-viruses/
Posted On: 05/18/2020 12:35:54 PM
Posted By: Sierra
Re: ronclaw47 #6162
NanoLogix Sub 1-Hour Covid-19 Detection Test Now
Patent-Pending
Patent Application Filed Under New COVID-19 Prioritized Examination Pilot Program
NanoLogix is pleased to announce the filing of a patent application for use in the rapid testing for the Covid-19 virus. The application was filed under a new program instituted May 14th by the US Patent and Trademark Office. Now that Patent-Pending status has been obtained, we can reveal aspects of the technology that we were unable to mention in a prior update.
This Rapid Viral Assay is a modified ELISA technology that is not the same as our N-Assay modified ELISA.
While the initial focus for development was for the COVID-19 virus, it became obvious that the technology is not limited to one virus, but can be configured for many different viruses, such as HIV, HPV, Hepatitis, MERS, SARS-1 and others. As per the patent filing, the description is "Without Limitation".
An additional aspect of the test is that for the Home-Test configuration, we anticipate the potential of 30-minute results using a nasopharyngeal swab sample or saliva.
Jonathan Faro, MD, PhD., our Chief Medical Officer stated "We are extremely excited over this technology development, as it is a novel approach in diagnostics that provides a solution to the inherent problems with false positives and false negatives present in those tests currently being used in the war against COVID-19."
The US Patent Office program under which the filing was done can be accessed through the following link:
https://www.federalregister.gov/documents/202...program?
Read More: https://investorshangout.com/post/view?id=577...z6N0UZkNXc
Read More: https://investorshangout.com/Nanologix-Inc-NN...z6WLcA5KqR
(6)
(0)Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼